Skip to main content
Top
Published in: Calcified Tissue International 6/2006

01-12-2006 | Laboratory Investigations

Comparison of Hypotensive Response following Intravenous Injection of Parathyroid Hormone 1-84 and 1-34 in Conscious Rats

Authors: K. R. Scott, J. Fox

Published in: Calcified Tissue International | Issue 6/2006

Login to get access

Abstract

Activation of parathyroid hormone 1 (PTH-1) receptors on vascular smooth muscle cells causes relaxation and decreases blood pressure in rats and humans. However, when PTH(1-84) and PTH(1-34) were injected in anesthetized rats, PTH(1-34) produced a greater decrease in blood pressure. This study quantified the dose-response relationship of the hypotensive response to intravenously injected PTH(1-84) and PTH(1-34) in conscious rats and assessed the role that the C-terminal region of PTH(1-84) played in the differences. Mean arterial pressure (MAP) decreased rapidly following injection of both peptides (0–100 nmol/kg) and reached a nadir at 1–2 minutes before increasing at a rate that was dose- and time-dependent. PTH(1-34) produced a greater hypotensive effect than PTH(1-84) at most doses tested and was significantly different from PTH(1-84) at 1–10 nmol/kg. The greatest difference in MAP decrease between PTH(1-84) and PTH(1-34) (24 and 35 mm Hg, respectively) occurred at 10 nmol/kg. Median effective dose (ED50) values for PTH(1–84) and PTH(1-34) were significantly different (5.9 and 1.3 nmol/kg, respectively). The C-terminal PTH fragments PTH(7–84), PTH(39–84), and PTH(53–84) did not affect MAP when injected alone (10 nmol/kg), nor did they influence the hypotensive response when given at a 10–fold molar excess in combination with PTH(1-84) or PTH(1-34) (1.4 nmol/kg). In conclusion, PTH(1-84) is a less potent but, because it induced the same maximum response, not a less efficacious hypotensive agent than PTH(1-34) when administered by bolus intravenous injection in conscious rats. We found no evidence to support the concept that the C-terminal region of PTH is responsible for this difference in potency.
Literature
1.
go back to reference Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709PubMedCrossRef Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709PubMedCrossRef
2.
go back to reference Fox J (2002) Developments in parathyroid hormone and related peptides as bone-formation agents. Curr Opin Pharmacol 2:338–344PubMedCrossRef Fox J (2002) Developments in parathyroid hormone and related peptides as bone-formation agents. Curr Opin Pharmacol 2:338–344PubMedCrossRef
3.
go back to reference Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ (1989) Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology 125:2022–2027PubMed Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ (1989) Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology 125:2022–2027PubMed
4.
go back to reference Mosekilde L, Søgaard CH, Danielsen CC, Tørring O (1991) The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129:421–428PubMed Mosekilde L, Søgaard CH, Danielsen CC, Tørring O (1991) The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129:421–428PubMed
5.
go back to reference Ejersted C, Andreassen TT, Oxlund H, Jørgensen PH, Bak B, Häggblad J, Tørring O, Nilsson MHL (1993) Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 8:1097–1101PubMedCrossRef Ejersted C, Andreassen TT, Oxlund H, Jørgensen PH, Bak B, Häggblad J, Tørring O, Nilsson MHL (1993) Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 8:1097–1101PubMedCrossRef
6.
go back to reference Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR (1993) The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577–1584PubMedCrossRef Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR (1993) The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577–1584PubMedCrossRef
7.
go back to reference Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517–1525PubMedCrossRef Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517–1525PubMedCrossRef
8.
go back to reference Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28:237–250PubMedCrossRef Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28:237–250PubMedCrossRef
9.
go back to reference Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Barbier JR, Isaacs RJ, Andreassen TT (2001) The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1–31)NH2 on bone formation and mechanical strength in ovariectomized rats. Calcif Tissue Int 68:95–101PubMed Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Barbier JR, Isaacs RJ, Andreassen TT (2001) The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1–31)NH2 on bone formation and mechanical strength in ovariectomized rats. Calcif Tissue Int 68:95–101PubMed
10.
go back to reference Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
11.
go back to reference Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5120PubMedCrossRef Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5120PubMedCrossRef
12.
go back to reference Greenspan SL, Bone HG, Marriott TB, Zanchetta JR, Ettinger MP, Hanley DA, Drezner MK, Miller PD (2005) Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP study [abstract]. J Bone Miner Res 20(suppl 1):S56 Greenspan SL, Bone HG, Marriott TB, Zanchetta JR, Ettinger MP, Hanley DA, Drezner MK, Miller PD (2005) Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP study [abstract]. J Bone Miner Res 20(suppl 1):S56
13.
go back to reference Gardella TJ, Jüppner H, Bringhurst FR, Potts JT Jr (2002) Receptors for parathyroid hormone (PTH) and PTH-related peptide. In: Bilezikian JP, Raisz LG, Rodan GA (eds), Principles of Bone Biology. Academic Press, San Diego, pp 389–405 Gardella TJ, Jüppner H, Bringhurst FR, Potts JT Jr (2002) Receptors for parathyroid hormone (PTH) and PTH-related peptide. In: Bilezikian JP, Raisz LG, Rodan GA (eds), Principles of Bone Biology. Academic Press, San Diego, pp 389–405
14.
go back to reference Pang PKT, Yang MCM, Tenner TE Jr, Kenny AD (1986) Cyclic AMP and the cardiovascular action of parathyroid hormone. Can J Physiol Pharmacol 64:1543–1547PubMed Pang PKT, Yang MCM, Tenner TE Jr, Kenny AD (1986) Cyclic AMP and the cardiovascular action of parathyroid hormone. Can J Physiol Pharmacol 64:1543–1547PubMed
15.
go back to reference Mok LLS, Nickols GA, Thompson JC, Cooper CW (1989) Parathyroid hormone as a smooth muscle relaxant. Endocr Rev 10:420–436PubMedCrossRef Mok LLS, Nickols GA, Thompson JC, Cooper CW (1989) Parathyroid hormone as a smooth muscle relaxant. Endocr Rev 10:420–436PubMedCrossRef
16.
go back to reference Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF (1996) Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76:127–173PubMed Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF (1996) Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76:127–173PubMed
17.
go back to reference Whitfield JF, Morley P, Ross V, Preston E, Soska M, Barbier J-R, Isaacs RJ, Maclean S, Ohannessian-Barry L, Willick GE (1997) The hypotensive actions of osteogenic and nonosteogenic parathyroid hormone fragments. Calcif Tissue Int 60:302–308PubMedCrossRef Whitfield JF, Morley P, Ross V, Preston E, Soska M, Barbier J-R, Isaacs RJ, Maclean S, Ohannessian-Barry L, Willick GE (1997) The hypotensive actions of osteogenic and nonosteogenic parathyroid hormone fragments. Calcif Tissue Int 60:302–308PubMedCrossRef
18.
go back to reference Roelen DL, Frolich M, Papapoulos SE (1989) Renal responsiveness to synthetic human parathyroid hormone 1–38 in healthy subjects. Eur J Clin Invest 19:311–315PubMed Roelen DL, Frolich M, Papapoulos SE (1989) Renal responsiveness to synthetic human parathyroid hormone 1–38 in healthy subjects. Eur J Clin Invest 19:311–315PubMed
19.
go back to reference Morimoto S, Imanaka S, Ogihara T (1989) Comparison of hypotensive effects of acutely administered human parathyroid hormone (1-34) in normal young and elderly subjects. Nippon Ronen Igakkai Zasshi 26:395–400PubMed Morimoto S, Imanaka S, Ogihara T (1989) Comparison of hypotensive effects of acutely administered human parathyroid hormone (1-34) in normal young and elderly subjects. Nippon Ronen Igakkai Zasshi 26:395–400PubMed
20.
go back to reference Suzuki T, Aoki K (1988) Hypertensive effects of calcium infusion in subjects with normotension and hypertension. J Hypertens 6:1003–1008PubMedCrossRef Suzuki T, Aoki K (1988) Hypertensive effects of calcium infusion in subjects with normotension and hypertension. J Hypertens 6:1003–1008PubMedCrossRef
21.
go back to reference Karanja N, McCarron DA (1986) Calcium and hypertension. Annu Rev Nutr 6:645–694CrossRef Karanja N, McCarron DA (1986) Calcium and hypertension. Annu Rev Nutr 6:645–694CrossRef
22.
go back to reference Cooper CW, Hirsch PF, Munson PL (1970) Importance of endogenous thyrocalcitonin for protection against hypercalcemia in the rat. Endocrinology 86:406–415PubMedCrossRef Cooper CW, Hirsch PF, Munson PL (1970) Importance of endogenous thyrocalcitonin for protection against hypercalcemia in the rat. Endocrinology 86:406–415PubMedCrossRef
23.
go back to reference Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, D’Amour P (2002) Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147:123–131PubMedCrossRef Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, D’Amour P (2002) Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147:123–131PubMedCrossRef
24.
go back to reference Bringhurst FR (2003) Circulating forms of parathyroid hormone: peeling back the onion. Clin Chem 49:1973–1975PubMedCrossRef Bringhurst FR (2003) Circulating forms of parathyroid hormone: peeling back the onion. Clin Chem 49:1973–1975PubMedCrossRef
25.
go back to reference Canterbury JM, Bricker LA, Levey GS, Kozlovskis PL, Ruiz E, Zull JE, Reiss E (1975) Metabolism of bovine parathyroid hormone. Immunological and biological characteristics of fragments generated by liver perfusion. J Clin Invest 55:1245–1253PubMed Canterbury JM, Bricker LA, Levey GS, Kozlovskis PL, Ruiz E, Zull JE, Reiss E (1975) Metabolism of bovine parathyroid hormone. Immunological and biological characteristics of fragments generated by liver perfusion. J Clin Invest 55:1245–1253PubMed
26.
go back to reference Hruska KA, Korkor A, Martin K, Slatopolsky E (1981) Peripheral metabolism of intact parathyroid hormone. Role of liver and kidney and the effect of chronic renal failure. J Clin Invest 67:885–892PubMed Hruska KA, Korkor A, Martin K, Slatopolsky E (1981) Peripheral metabolism of intact parathyroid hormone. Role of liver and kidney and the effect of chronic renal failure. J Clin Invest 67:885–892PubMed
27.
go back to reference Goltzman D, Bennett HPJ, Koutsilieris M, Mitchell J, Rabbani SA, Rouleau MF (1986) Studies of the multiple molecular forms of bioactive parathyroid hormone and parathyroid hormone-like substances. Recent Prog Horm Res 42:665–697PubMed Goltzman D, Bennett HPJ, Koutsilieris M, Mitchell J, Rabbani SA, Rouleau MF (1986) Studies of the multiple molecular forms of bioactive parathyroid hormone and parathyroid hormone-like substances. Recent Prog Horm Res 42:665–697PubMed
28.
go back to reference Zhang C-X, Weber BV, Thammavong J, Grover TA, Wells DS (2006) Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 78:1636–1643PubMedCrossRef Zhang C-X, Weber BV, Thammavong J, Grover TA, Wells DS (2006) Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 78:1636–1643PubMedCrossRef
29.
go back to reference Bringhurst FR, Stern AM, Yotts M, Mizrahi N, Segre GV, Potts JT Jr (1988) Peripheral metabolism of PTH: fate of the biologically active amino terminus in vivo. Am J Physiol 255:E886–E893PubMed Bringhurst FR, Stern AM, Yotts M, Mizrahi N, Segre GV, Potts JT Jr (1988) Peripheral metabolism of PTH: fate of the biologically active amino terminus in vivo. Am J Physiol 255:E886–E893PubMed
30.
go back to reference Inomata N, Akiyama M, Kubota N, Jüppner H (1995) Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 136:4732–4740PubMedCrossRef Inomata N, Akiyama M, Kubota N, Jüppner H (1995) Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 136:4732–4740PubMedCrossRef
31.
go back to reference Murray TM, Rao S, Divieti P, Bringhurst FR (2005) Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 26:78–113PubMedCrossRef Murray TM, Rao S, Divieti P, Bringhurst FR (2005) Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 26:78–113PubMedCrossRef
32.
go back to reference Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753–761PubMedCrossRef Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753–761PubMedCrossRef
33.
go back to reference Nguyen-Yamamoto L, Rousseau L, Brossard J-H, Lepage R, D’Amour P (2001) Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386–1392PubMedCrossRef Nguyen-Yamamoto L, Rousseau L, Brossard J-H, Lepage R, D’Amour P (2001) Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386–1392PubMedCrossRef
34.
go back to reference Langub MC, Monier-Faugere M-C, Wang G, Williams JP, Koszewski NJ, Malluche HH (2003) Administration of PTH-(7–84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144:1135–1138PubMedCrossRef Langub MC, Monier-Faugere M-C, Wang G, Williams JP, Koszewski NJ, Malluche HH (2003) Administration of PTH-(7–84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144:1135–1138PubMedCrossRef
35.
go back to reference Divieti P, John MR, Jüppner H, Bringhurst FR (2002) Human PTH-(7–84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143:171–176PubMedCrossRef Divieti P, John MR, Jüppner H, Bringhurst FR (2002) Human PTH-(7–84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143:171–176PubMedCrossRef
36.
go back to reference Murray TM, Rao LG, Muzaffar SA (1991) Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide PTH (53–84): stimulation of alkaline phosphatase. Calcif Tissue Int 49:120–123PubMed Murray TM, Rao LG, Muzaffar SA (1991) Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide PTH (53–84): stimulation of alkaline phosphatase. Calcif Tissue Int 49:120–123PubMed
37.
go back to reference Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439–446PubMedCrossRef Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439–446PubMedCrossRef
38.
go back to reference Divieti P, Inomata N, Chapin K, Singh R, Jüppner H, Bringhurst FR (2001) Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142:916–925PubMedCrossRef Divieti P, Inomata N, Chapin K, Singh R, Jüppner H, Bringhurst FR (2001) Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142:916–925PubMedCrossRef
39.
go back to reference Vahle JL, Sato M, Long GG (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321PubMedCrossRef Vahle JL, Sato M, Long GG (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321PubMedCrossRef
40.
go back to reference Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS (2006) Defining a non-carcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol (in press) Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS (2006) Defining a non-carcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol (in press)
41.
go back to reference Physicians’ Desk Reference, 59th ed (2005) Thomson Healthcare, Montvale, NJ, p 1842 Physicians’ Desk Reference, 59th ed (2005) Thomson Healthcare, Montvale, NJ, p 1842
Metadata
Title
Comparison of Hypotensive Response following Intravenous Injection of Parathyroid Hormone 1-84 and 1-34 in Conscious Rats
Authors
K. R. Scott
J. Fox
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2006
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-006-0175-3

Other articles of this Issue 6/2006

Calcified Tissue International 6/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine